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Background: Over the last 100 years, several persistent misconceptions or ‘false beliefs’ have built up around
allergen immunotherapy and its use in allergic rhinitis. This is perhaps because enthusiastic physicians administered
complex allergen extracts to a diverse population of patients suffering from heterogeneous atopic conditions. Here,
we review evidence that counters seven of these ‘false beliefs.’
Discussion: 1. The symptoms of allergic rhinitis can be more heterogeneous, more severe and more troublesome
in everyday life than many physicians believe. Large-scale epidemiological surveys show that the majority of allergic
rhinitis patients have at least one symptom severe enough to interfere with sleep quality, productivity and/or well-
being. 2. Allergen immunotherapy is not necessarily suitable for all allergic rhinitis patients (notably those with mild
symptoms). Recent evidence from double-blind, placebo-controlled, randomized clinical trials suggests that the
more severe the disease, the greater the treatment effect. 3. Allergen immunotherapy is often accused of lack of
efficacy (relative to pharmacotherapy, for example). However, there are now many meta-analyses, systematic
reviews and high-quality clinical trials that find overwhelmingly in favor of the efficacy of allergen immunotherapy
(including sublingual formulations) in allergic rhinitis induced by pollen and, increasingly, other allergens.
4. Natural-exposure and challenge-chamber trials have shown that symptom relief may become apparent within
months or even weeks of the initiation of allergen immunotherapy. 5. In pollen-induced allergic rhinitis, several
years of subcutaneous or sublingual allergen immunotherapy are associated with sustained clinical efficacy after
subsequent treatment cessation – confirming the disease-modifying nature of this therapy. 6. Most patients seeking
treatment for allergic rhinitis are polysensitized, and allergen immunotherapy has proven efficacy in large, robust
clinical trials in these groups. Polysensitization is not a contraindication to allergen immunotherapy. 7. Sublingual
allergen immunotherapy is safe for home administration. A recent review calculated that 1 billion doses were
administered worldwide between 2000 and 2010 and found that the 11 case reports of anaphylaxis (all non-fatal)
corresponded to non-standard practice.
Summary: Modern, evidence-based medicine has generated more than enough robust evidence to remove
misconceptions about allergen immunotherapy and allergic rhinitis.
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In 2011, a flurry of events and publications marked the
centenary of Leonard Noon and John Freeman's ground-
breaking papers in The Lancet - the first scientific descrip-
tions of clinically effective allergen immunotherapy (AIT)
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2013However, several persistent misconceptions or ‘false beliefs’
have built up around AIT and its use in allergic rhinitis
(AR) over the last 100 years. These misconceptions largely
arose because of the empirical, poorly standardized clinical
research methods that were widely used in this field until
the 1950s. In a sense, Noon and Freeman were ahead of
their time in describing their research so precisely and ele-
gantly; their reports triggered attempts by enterprising,
enthusiastic physicians to administer complex therapeutics
to a diverse population of patients suffering from het-
erogeneous medical conditions [3]. Unsurprisingly, theal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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munotherapy involves the regular administration of
specific, semipurified allergen extracts, with a view to
desensitizing the patient's allergic reaction when the
sensitizing allergen is subsequently or concomitantly
encountered under ‘natural exposure’ conditions. Al-
though the molecular and cellular details of AIT's
mechanism of action are still being worked out, the in-
duction of peripheral T cell tolerance by T regulatory
cells is a key step in shifting the immune response to
an allergen from a ‘T-helper 2’ profile to a tolerogenic
‘T-helper 1’ profile [4]. Historically, a subcutaneous in-
jection every month or two has been the preferred
route for the administration of allergen extracts. How-
ever, subcutaneous AIT (SCIT) is associated with a low
but non-negligible risk of systemic and potentially ana-
phylactic reactions and other administration routes
have been developed (with a recent emphasis on deliv-
ery to the sublingual mucosa) in order to improve the
safety profile while maintaining efficacy. However, after
a hundred years of clinical experimentation, there is lit-
tle consensus on the optimal regimen for a given aller-
gen extract and administration route (in terms of the
frequency of administration, the dose of allergen ad-
ministered each time, the duration of treatment and,
thus, the cumulative dose). Here, we briefly review a
number of persistent misconceptions and cite some of
the robust medical and scientific evidence that should
lay these false beliefs to rest at last.
Discussion
False belief #1: ‘Allergic rhinitis is a trivial, homogenous
disease’
In fact, AR is under-diagnosed and undertreated, and its
symptoms are more troublesome than many physicians
(and indeed some patients) believe. In a Europe-wide
survey, two-thirds of AR patients reported at least one
symptom that is severe enough to interfere with sleep
quality, cognitive function, work productivity, school
performance, psychosocial well-being or overall quality
of life [5]. Poor sleep is a particular problem. In a study
in France, 44% of AR patients reported feeling tired after
a night’s sleep and were also more prone to anxiety and
depression [6]. In another Europe-wide survey, one-third
of patients felt irritable and 12% of both persistent and
intermittent sufferers suffered from depression [7]. The
study also emphasized the association between disease
severity and the presence of comorbidities (including po-
tentially life-threatening asthma); one third of the sur-
veyed AR patients had been diagnosed with asthma and
three-quarters of the asthma sufferers had moderate-to-
severe AR [7]. We acknowledge that state social security
systems may no longer be able to bear the full financial
burden of AR, as they face other challenges broughtabout by the economic global crisis and demands linked
to rarer but more severe diseases (such as cancer and
neurodegenerative disorders), in comparison with which
AR is trivial. However, the immediate consequence of
trivializing AR is suboptimal treatment and altered well-
being and function for a great number of citizens. In a
Danish survey, 83% of patients with moderate-to-severe
rhinitis were undertreated (that is, they were receiving
antihistamines only or even no treatment at all) [8].
False belief #2: ‘Allergen immunotherapy is indicated in
all allergic rhinitis sufferers’
International guidelines and consensus statements (such
as those issued by the Allergic Rhinitis and its Impact
on Asthma group) [9] make it very clear that AIT is a
second-line treatment for use when AR is severe or
poorly controlled by appropriate pharmacotherapy or
when pharmacotherapy is refused by the patient or in-
duces undesirable side effects. The guidelines also state
that AIT is particularly appropriate in patients suffering
from moderate-to-severe AR in whom symptomatic
treatments are inefficacious, poorly tolerated or not
wanted. There is good evidence that AIT is very suitable
for highly symptomatic patients. For example, a post-hoc
analysis of large subgroups of AR patients receiving
grass pollen sublingual allergen immunotherapy (SLIT)
[10] found that the relative active versus placebo differ-
ences in the symptom score were, respectively, 15%, 26%
and 37% in investigating centers likely to have low, mod-
erate and high disease activity (as defined by the symp-
tom scores in the placebo-treated groups). In a similar
pediatric trial, centers with low, moderate and severe
disease activity had relative active versus placebo differ-
ences of 10%, 33% and 34%, respectively. Hence, al-
though a treatment effect was seen in patient groups
with low initial symptom scores, the magnitude of the
effect was greater in groups with higher initial scores.
Using a different approach (based on an analysis of the
frequency of ‘days with severe symptoms’ in individual
patients), Durham et al. [11] came to the same conclu-
sion: the more severe the symptoms, the greater the
clinical impact of grass pollen SLIT.
False belief #3: ‘Sublingual allergen immunotherapy is
not efficacious in allergic rhinitis’
With so many meta-analyses ([12], for example), in-
depth reviews [13,14] and high-quality, well-powered
double-blind, placebo-controlled, randomized clinical
trials (DBPC RCTs) ([15,16], for example) finding in
favor of SLIT in pollen-induced AR, it is hard to see
why this false belief persists. The sometimes conflicting
results of studies published before the 1980s (often with
small study populations and non-optimal trial designs)
may have been responsible for lingering doubt as to the
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mechanism of action. The efficacy of SLIT in pollen-
induced AR is beyond doubt and our knowledge of how
AIT may work is now far more robust [4]. We firmly be-
lieve that in time, the remaining question marks over
the efficacy of AIT in the treatment of AR induced by
other allergens (for example, house dust mite allergens)
will be dispelled by methodical clinical investigation.
False belief #4: ‘Allergen immunotherapy does not have
short-term clinical benefits in allergic rhinitis’
The fact that several consecutive seasons or years of
AIT are recommended may have inspired the miscon-
ception that this therapy only becomes effective after
several years. Noon and Freeman noted clinical effects
after treating patients ‘from a few weeks to eight months’
[1,2,17]. The vast majority of recent, large-scale trials
involved two to four months of pre-seasonal treatment
before the pollen season in which significant clinical effi-
cacy was observed [12-16]. In a DBPC RCT of patients
taking sublingual grass pollen tablets, controlled expos-
ure to pollen outside the season (in an allergen challenge
chamber) at treatment initiation and one week and one,
two and four months thereafter showed that the active
versus placebo difference in symptom score became sta-
tistically significant at one month [18]. Hence, SLIT has
clinical benefits after just a few weeks of administration.
False belief #5: ‘There is no sustained effect after
discontinuation of allergen immunotherapy’
This misconception is hard to equate with the previous
one, since AIT would then have neither short-term nor
long-term efficacy. Allergen immunotherapy differs
markedly from symptomatic drugs in that it can produce
sustained symptom relief after treatment discontinuation
[19]. For example, a study involving 257 subjects with
grass pollen rhinoconjunctivitis (who had been random-
ized to three years of daily treatment with grass pollen
SLIT tablets or placebo) found that clinical improve-
ments and accompanying immunological changes were
sustained for at least two years [20]. In addition to in-
creasing efficacy from one season to another while on
AIT tablets, patients showed a similar, sustained reduc-
tion in symptom and medication scores one year after
treatment cessation (with mean reductions of 26% and
29%, respectively). However, the recent, large-scale clin-
ical trials demonstrating the post-treatment efficacy of
grass pollen SCIT and SLIT involved three previous
treatment seasons; it appears that sustained treatment is
required for sustained post-treatment efficacy and that
(with today's allergen formulations, at least) a single
season or year of treatment is not sufficient. As with
any chronic regimen, AIT thus requires good levels
of patient compliance to be efficacious. Furthermore,allergens other than grass pollen remain to be investi-
gated in detail. Nevertheless, AIT is clearly a disease-
modifying treatment – something that antihistamines
and corticosteroids will never be.
False belief #6: ‘Allergen immunotherapy is not
appropriate in polysensitized patients’
This misconception is only slightly less sensible than say-
ing ‘antihistamines are not appropriate in polysensitized
patients.’ Allergen immunotherapy has proven efficacy in
large, robust clinical trials in primarily polysensitized pa-
tients [21]; it would be hard to achieve such a significant
overall treatment effect through high efficacy in a minority
of patients. Indeed, post-hoc analyses have confirmed that
sensitization status was not a significant covariate in
placebo-controlled efficacy in two large trials [22,23].
False belief #7: ‘Home administration of SLIT with
inhalant allergens is not safe’
It is absolutely clear that sublingual formulations of
inhalant allergens have an excellent safety profile – per-
haps the best of any therapeutic used to treat allergic
disease. A recent review of 11 case reports of anaphyl-
axis (all non-fatal) found that none corresponded to
standard practice in SLIT [24]; in fact, the events in-
volved non-standardized extracts, rush protocols, over-
doses and patients who had previously discontinued
SCIT due to serious adverse reactions. The authors cal-
culated that one billion SLIT doses had been adminis-
tered worldwide between 2000 and 2010 (that is, one
case of anaphylaxis per 100 million SLIT administrations
or one per 526,000 treatment years). This excellent
safety profile may be due to rapidly occurring antigen
capture by local, tolerogenic antigen-presenting cells and
the low numbers of mast cells in sublingual tissues [24].
Nevertheless, all physicians prescribing allergen im-
munotherapy (and, indeed, all patients receiving it)
should be aware of the risk of anaphylaxis and know
how to recognize and treat the condition (or seek treat-
ment) promptly.
False belief #8: ‘Allergic disease is constant over a
patient's lifetime’
There is sound epidemiological evidence to show that
the activity of allergic respiratory diseases changes with
age and that children develop and/or display atopy
within the first years or even months of life [25]. In gen-
eral, the ‘allergic march’ means that many AR sufferers
will develop allergic asthma (AA) (and vice versa). Con-
versely, some patients will "outgrow" one or more of
their allergies (essentially during adolescence) [26]. The
chronology of the natural history of AR and AA raises
the question of the age at which a disease-modifying
treatment, such as AIT, could be introduced in atopic
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compliance reasons, AIT is only suitable for children
over the age of 5. However, in view of the early onset of
atopy, we consider than clinical investigations of AIT in
under-fives are ethically justified. There is also a need to
develop allergy prevention strategies (the best being
breastfeeding, at present) and test novel, minimally inva-
sive formulations that are suitable for use in young chil-
dren (such as allergen patches) and that may facilitate
extension of the robust evidence on pollen AIT to food
allergies [27].
Summary
Allergic rhinitis is a heterogeneous, under-diagnosed,
undertreated, chronic, allergic respiratory condition. If
physicians disregard the severity of symptoms, AR suf-
ferers will remain exposed to co-morbidities and poor
quality of life. Leonard Noon and John Freeman's
ground-breaking papers in 1911 prompted enthusiastic
but empirical and sometimes unethical clinical practice
and research in the field of allergen immunotherapy in
the first half of the 20th century. As a result, allergen
immunotherapy for AR has long suffered from the per-
sistence of ‘false beliefs’ driven by poor methodology.
Despite being a guidelines-recommended treatment,
AIT is often not considered by the physician. However,
there is now more than enough evidence from recent
robust DBPC RCTs, meta-analyses and large-scale epi-
demiological surveys to allay misconceptions about
AIT – the only disease-modifying treatment for respira-
tory allergies. In appropriately screened patients, modern
AIT is undoubtedly safe and effective in the treatment of
AR induced by common aeroallergens.
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